Payment overview · 2025
General Payments
$584.30
26 reported records · 10 companies
Healthcare provider profile · identity verified
Melanie Ann Powell, DO
Allopathic & Osteopathic Physicians|Family Medicine · BORDENTOWN, NJ · NPI 1811973464
Verified facts
What the public records show
CMS Open Payments records show Melanie Ann Powell, DO received $584.30 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $284.08 | 48.6% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.08 | 15.6% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.52 | 9.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.69 | 8.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.70 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.66 | 3.2% | 1 | 2025 |
| ModernaTX, Inc. | Unresolved — no canonical attribution shown | $18.00 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.36 | 2.8% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.32 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.89 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $584.30 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $232.07 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.77 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.54 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.54 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.01 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.69 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.54 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| mResvia Normalized: mresvia |
Drug | ModernaTX, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 55 |
| Gabapentin | Gabapentin | 182 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 62 |
| Omeprazole | Omeprazole | 170 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 45 |
| Alprazolam | Alprazolam | 163 | 32 |
| Lisinopril | Lisinopril | 162 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 41 |
| Metformin Hcl | Metformin Hcl | 138 | 42 |
| Losartan Potassium | Losartan Potassium | 126 | 36 |
| Sertraline Hcl | Sertraline Hcl | 123 | 36 |
| Bupropion Xl | Bupropion Hcl | 107 | 18 |
| Montelukast Sodium | Montelukast Sodium | 101 | 27 |
| Simvastatin | Simvastatin | 99 | 30 |
| Metformin Hcl Er | Metformin Hcl | 97 | 33 |
| Trazodone Hcl | Trazodone Hcl | 95 | 18 |
| Famotidine | Famotidine | 93 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 45 |
| Lorazepam | Lorazepam | 74 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 13 |
| Tramadol Hcl | Tramadol Hcl | 64 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 11 |
| Meloxicam | Meloxicam | 60 | 15 |
| Ozempic | Semaglutide | 59 | suppressed |
| Carvedilol | Carvedilol | 58 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Potassium Chloride | Potassium Chloride | 53 | 14 |
| Ondansetron Odt | Ondansetron | 52 | 13 |
| Furosemide | Furosemide | 51 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 13 |
| Eliquis | Apixaban | 50 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 12 |
| Ezetimibe | Ezetimibe | 49 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 12 |
| Allopurinol | Allopurinol | 45 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Prednisone | Prednisone | 45 | 37 |
| Ibuprofen | Ibuprofen | 41 | 12 |
| Lidocaine | Lidocaine | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 11 |
| Glipizide Er | Glipizide | 34 | 11 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Nystatin | Nystatin | 30 | 14 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $584.30 · 26 records | Novo Nordisk Inc | ABRYSVO, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, GARDASIL 9, ImmunoCAP, KISUNLA, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, PROQUAD, REXULTI, Rybelsus, VAXELIS, VRAYLAR, Wegovy, ZEPBOUND, mResvia | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error